Bausch Health Cos — Business Overview

What does Bausch Health do?

Bausch Health is a global specialty pharmaceutical and medical device company selling branded, generic, and over-the-counter health products across five distinct business segments. It develops, manufactures, and markets products primarily in gastroenterology, hepatology, neurology, dermatology, and eye health, selling to physicians, hospitals, pharmacies, and wholesalers in roughly 90 countries. The company had total revenues of $10.27 billion in 2025.

Bausch + Lomb is a distinct publicly traded company (~88% owned by Bausch Health) and the largest piece of the business. It operates as a separately listed entity on both the New York and Toronto stock exchanges under the ticker "BLCO." Bausch Health has been pursuing a full separation of Bausch + Lomb — which would result in two independent companies — though that separation remains conditional on achieving certain debt targets and other approvals.

How does Bausch Health make money?

The majority of Bausch Health's revenue comes from selling branded prescription drugs, with a single product — Xifaxan — representing an outsized share. Xifaxan alone generated $2.21 billion in 2025 revenue, roughly 22% of the company's total, making it the clearest example of what the industry calls a high-margin branded drug (a drug protected by patents that commands a premium price with limited competition). The Salix segment, which is essentially synonymous with Xifaxan in the U.S., is the company's most profitable business unit.

Beyond Salix, revenue is spread across a diversified portfolio of branded, generic, OTC, and device products. The Bausch + Lomb segment adds a meaningful recurring revenue stream from consumables like contact lenses and lens care solutions — products people repurchase regularly — alongside more episodic revenue from surgical equipment. Solta Medical earns revenue from selling aesthetic treatment devices (like its skin-tightening Thermage systems) to medical providers. This mix of prescription, OTC, device, and consumable revenue provides some diversification, even if Xifaxan remains the single most important product financially.

Three pharmaceutical distributors together account for nearly half of all company revenue. Cencora (18%), McKesson (16%), and Cardinal Health (14%) are the dominant U.S. drug wholesalers through which Bausch Health sells its products. This level of customer concentration is common in pharma but means that any disruption in those relationships would have an immediate impact on sales.

What market does Bausch Health operate in?

Bausch Health competes in the global specialty pharmaceutical and medical device industries — large, regulated, and highly competitive markets. Specialty pharma focuses on complex or hard-to-treat conditions (like IBS-D or hepatic encephalopathy) rather than mass-market primary care, and typically commands higher prices than general medicines. The medical device side (primarily through Bausch + Lomb and Solta Medical) adds exposure to surgical equipment, contact lenses, and aesthetic technology markets.

Several secular trends shape the company's environment, some favorable, some not. On the positive side, aging populations drive increased demand for eye health products, GI treatments, and neurological medications. Growing consumer interest in aesthetic procedures supports Solta Medical. On the negative side, the U.S. government's Inflation Reduction Act (IRA) now allows Medicare to directly negotiate drug prices — and Xifaxan 550mg has already been selected for price negotiation, with a negotiated price taking effect January 1, 2027. Generic drug competition also remains a persistent threat: when a branded drug's patent expires, generics typically capture rapid market share at much lower prices.

Who are Bausch Health's main competitors?

The pharmaceutical and device industries in which Bausch Health operates are highly competitive and, depending on the segment, either consolidated or fragmented. In GI, larger specialty pharma companies compete directly. In dermatology, the landscape is described as highly fragmented, with many mid-size and smaller players. In eye health, Bausch + Lomb faces both large diversified companies (like Alcon and Johnson & Johnson Vision) and smaller niche players.

Bausch Health's primary competitive advantages rest on its branded products, patents, and established commercial infrastructure. Its large salesforce, direct-to-consumer advertising (notably for Xifaxan), and portfolio breadth allow it to compete across multiple therapeutic areas simultaneously. However, patent protection is the most critical moat — and the company is actively litigating against generic manufacturers challenging patents on both Xifaxan and Trulance. A successful generic challenge could dramatically erode Salix revenue. The filing notes that a generic version of Xifaxan is currently expected no earlier than January 2028.

Where does Bausch Health operate?

The U.S. is Bausch Health's most important market, accounting for approximately 60% of total 2025 revenues. The company sells through its own salesforce to U.S. physicians, hospitals, and pharmacies, and manufactures across approximately 37 facilities worldwide, 25 of which belong to Bausch + Lomb.

Internationally, the company operates across roughly 90 countries, with China being the only single country flagged at 5% of revenues. No other non-U.S., non-Canada country exceeds 5% of sales. Key international regions include Europe (notably Poland and Central/Eastern Europe for the International segment), Latin America (Mexico, Central America), Asia-Pacific, the Middle East, and Africa. Approximately 7,100 employees are based in Europe and 2,550 in Asia-Pacific, reflecting meaningful operational scale in those regions.

The filing explicitly flags the usual risks of international operations — currency fluctuations, political instability, price controls, and government reimbursement policies — all of which can affect profitability in markets outside North America. Roughly 450 employees are based in Russia, which represents a geopolitical exposure worth noting given the current global environment.